Stempoint Capital LP 13F Portfolio

CIK 1952142 Filing since Q4 2023 Q3 2026 filed Nov 16, 2026
Holdings as of Sep 30, 2026, from the 13F filed Nov 16, 2026.

Portfolio Snapshot

71 positions · Q3 2026

Stempoint Capital LP reported 71 positions worth $533.46M for the quarter ended Sep 30, 2026, down 7.5% on the prior quarter. It opened 29 new positions, added to 18, trimmed 22 and exited 30. Its largest holding is Scholar Rock Holding Corp at 6.2% of the portfolio.

Portfolio Value
$533.46M
-7.5% QoQ · +18.9% YoY
Positions
71
29 new · 30 sold out
Top 10 Concentration
41.4%
of portfolio value
Largest Position
SRRK 6.2%
Scholar Rock Holding Corp
Net Buying
-$3.04M
$246.86M bought · $249.90M sold
Turnover
44.5%
of the portfolio traded
Top Sector
Healthcare
99.7% of value
Track Record
12
quarters on file since Q4 2023

Portfolio Value & Positions

Value Positions

Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.

Sector Allocation

2 sectors
99.66%
Healthcare
Healthcare99.66%
Financial Services0.342%

Quarterly Buying & Selling

Bought Sold

Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.

Position Changes

How many positions were opened, added to, trimmed or closed each quarter.

Sector Allocation Over Time

Share of reported value in each sector at every quarter end.

HealthcareFinancial ServicesOther

Largest Buys

Q3 2026
Holding Change Change % Trade Value Weight
SRRK Scholar Rock Holding Corp +449.8K +188.1% $21.73M 6.24%
ADPT Adaptive Biotechnologies Corp +463.6K – $13.40M 2.51%
IMTX Immatics N.V. +1.31M – $11.49M 2.15%
GRAL GRAIL, Inc. +81.9K – $11.48M 2.15%
ACRS Aclaris Therapeutics, Inc. +2.05M – $10.79M 2.02%
ROIV Roivant Sciences Ltd. +293.1K +84.1% $10.72M 4.4%
ERAS Erasca, Inc. +694.7K +44.4% $10.18M 6.21%
CCCC C4 Therapeutics, Inc. +2.77M +528.9% $9.22M 2.06%
ONC BeOne Medicines Ltd. +25.1K – $9.17M 1.72%
JNJ Johnson & Johnson +30.0K – $7.94M 1.49%

Largest Sells

Q3 2026
Holding Change Change % Trade Value Weight
RVMD Revolution Medicines, Inc. -109.9K -68.7% $22.57M 1.92%
TYRA Tyra Biosciences, Inc. -632.8K -100.0% $20.21M Exited
KNSA Kiniksa Pharmaceuticals International, plc -157.4K -75.2% $11.75M 0.725%
BIOA BioAge Labs, Inc. -464.2K -100.0% $11.38M Exited
MLYS Mineralys Therapeutics, Inc. -402.7K -66.8% $10.12M 0.942%
CLYM Climb Bio, Inc. -742.7K -100.0% $9.69M Exited
BHVN Biohaven Ltd. -667.3K -62.7% $8.91M 0.993%
ZURA Zura Bio Ltd -1.37M -100.0% $8.07M Exited
ORKA Oruka Therapeutics, Inc. -89.2K -76.6% $7.43M 0.426%
CGON CG Oncology, Inc. -104.6K -65.6% $7.41M 0.728%

New Positions

Q3 2026
Holding Shares Trade Value Weight
ADPT Adaptive Biotechnologies Corp +463.6K $13.40M 2.51%
IMTX Immatics N.V. +1.31M $11.49M 2.15%
GRAL GRAIL, Inc. +81.9K $11.48M 2.15%
ACRS Aclaris Therapeutics, Inc. +2.05M $10.79M 2.02%
ONC BeOne Medicines Ltd. +25.1K $9.17M 1.72%
JNJ Johnson & Johnson +30.0K $7.94M 1.49%
TRVI Trevi Therapeutics, Inc. +552.2K $7.91M 1.48%
LLY ELI LILLY & Co +6,599 $7.64M 1.43%
CERS Cerus Corp +2.97M $7.06M 1.32%
JBIO Jade Biosciences, Inc. +471.7K $6.63M 1.24%

Closed Positions

Q3 2026
Holding Shares Sold Trade Value Prior Weight
TYRA Tyra Biosciences, Inc. -632.8K $20.21M 3.5%
BIOA BioAge Labs, Inc. -464.2K $11.38M 1.97%
CLYM Climb Bio, Inc. -742.7K $9.69M 1.68%
ZURA Zura Bio Ltd -1.37M $8.07M 1.4%
AMLX Amylyx Pharmaceuticals, Inc. -384.3K $6.90M 1.2%
CLDX Celldex Therapeutics, Inc. -178.4K $6.64M 1.15%
EQ Equillium, Inc. -2.02M $6.45M 1.12%
DFTX Definium Therapeutics, Inc. -137.1K $6.45M 1.12%
IVA Inventiva S.A. -1.43M $5.39M 0.935%
EYPT EyePoint, Inc. -338.5K $4.84M 0.839%
Holdings · Q3 2026

71 Positions

As ofSep 30, 2026
Value$533.46M
Top 1041.4%
Avg position$7.51M
# Activity
56 more holdings Create a free account to keep reading this institution’s full portfolio.
Showing 1–15 of 71 positions 13F filings on SEC EDGAR

Tip. Select a row to see that position’s full history at Stempoint Capital.

About Stempoint Capital LP’s 13F Portfolio

What are Stempoint Capital LP’s largest holdings?

As of its Q3 2026 13F filing, Stempoint Capital LP’s five largest positions were Scholar Rock Holding Corp (SRRK) at 6.2%, Erasca, Inc. (ERAS) at 6.2%, Abivax S.A. (ABVX) at 5.2%, Tango Therapeutics, Inc. (TNGX) at 4.6%, Roivant Sciences Ltd. (ROIV) at 4.4% of the reported portfolio.

How much is Stempoint Capital LP’s portfolio worth?

Stempoint Capital LP reported a 13F portfolio worth $533.46M across 71 positions for Q3 2026. That is down 7.5% from the previous quarter.

What did Stempoint Capital LP buy in Q3 2026?

Its largest purchases by value were Scholar Rock Holding Corp ($21.73M), Adaptive Biotechnologies Corp ($13.40M), Immatics N.V. ($11.49M). It opened 29 new positions.

What did Stempoint Capital LP sell in Q3 2026?

Its largest sales by value were Revolution Medicines, Inc. ($22.57M), Tyra Biosciences, Inc. ($20.21M), Kiniksa Pharmaceuticals International, plc ($11.75M). It exited 30 positions entirely.

Where does this data come from?

From the Form 13F-HR reports Stempoint Capital LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.

Similar-Sized Institutions

by reported 13F value

13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.